Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®)-Reference-Cited by-同舟云学术

Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®)

Published:2011-03-08 Issue:3 Volume:17 Page:407-411
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:

Author:

BACON C. L.,SINGLETON E.,BRADY B.,WHITE B.,NOLAN B.,GILMORE R. M.,RYAN C.,KEOHANE C.,VINCE JENKINS P.,O’DONNELL J. S.

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2516.2010.02430.x/fullpdf

Reference33 articles.

1. Inhibitor development;Astermark;Haemophilia,2008

2. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs;Ehrenforth;Lancet,1992

3. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group;Lusher;N Engl J Med,1993

4. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors;McMillan;Blood,1988

5. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. French Hemophilia Study Group;Sultan;Thromb Haemost,1992

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. No immunological changes after factor VIII product switch: An in depth analysis in haemophilia A patients;Haemophilia;2023-06-05

2. Real pandemic world results of pharmacokinetic-tailored personalized prophylaxis of bleeds in Polish children and adolescents with severe hemophilia A;Frontiers in Pediatrics;2023-02-23

3. Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years;The Lancet Haematology;2022-09

4. Development of Haemophilia Treatment in the Eastern Part of Germany over the Last Decade in the Kompetenznetz Hämorrhagische Diathese Ost (KHDO);Hämostaseologie;2019-11-11

5. A prospective surveillance study of inhibitor development in haemophilia A patients following a population switch to a third-generation B-domain-deleted recombinant factor VIII;Haemophilia;2018-02-01